LETTER TO THE EDITOR
A standardized immunosuppressive regimen for patients who received liver transplantations treated with atezolizumab–bevacizumab to avoid graft rejection?
Edouard Larrey,
Edouard Larrey
Service d’Hépato-gastroentérologie, AP-HP Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière, Paris, France
Search for more papers by this author Filomena Conti,
Filomena Conti
Service d’Hépato-gastroentérologie, AP-HP Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière, Paris, France
Search for more papers by this author Manon Allaire,
Corresponding Author
Manon Allaire
Service d’Hépato-gastroentérologie, AP-HP Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière, Paris, France
Correspondence
Manon Allaire, Service d’hépato-gastroentérologie et oncologie, Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France.
Email: [email protected]
Search for more papers by this author
Edouard Larrey,
Edouard Larrey
Service d’Hépato-gastroentérologie, AP-HP Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière, Paris, France
Search for more papers by this author Filomena Conti,
Filomena Conti
Service d’Hépato-gastroentérologie, AP-HP Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière, Paris, France
Search for more papers by this author Manon Allaire,
Corresponding Author
Manon Allaire
Service d’Hépato-gastroentérologie, AP-HP Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière, Paris, France
Correspondence
Manon Allaire, Service d’hépato-gastroentérologie et oncologie, Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France.
Email: [email protected]
Search for more papers by this author
First published: 09 April 2022
No abstract is available for this article.
REFERENCES
- 1Yang Z, Sun J, Zhuang L, Mou H, Zheng S. Preliminary evaluation of atezolizumab plus bevacizumab as salvage treatment for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl. 2022; 28: 895–6.
- 2Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020; 382: 1894–905.
- 3Nguyen LS, Ortuno S, Lebrun-Vignes B, Johnson DB, Moslehi JJ, Hertig A, et al. Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review. Eur J Cancer. 2021; 148: 36–4.
